Immediate Management of Neonatal Seizures
Phenobarbital at 20 mg/kg IV is the first-line treatment for neonatal seizures regardless of etiology, with the exception of suspected channelopathy where a sodium channel blocker should be used instead. 1
Initial Stabilization and Assessment
When a neonate develops seizures shortly after delivery, immediately:
- Secure airway, breathing, and circulation - Ensure adequate oxygenation and ventilation
- Check point-of-care glucose and correct hypoglycemia immediately if present
- Obtain IV access for medication administration
- Begin continuous EEG monitoring as soon as feasible, since up to 50% of neonatal seizures are electrographic-only without clinical manifestations 2
First-Line Pharmacotherapy
Administer phenobarbital 20 mg/kg IV as initial treatment for most neonatal seizures (HIE, stroke, hemorrhage). 1 This recommendation is supported by moderate-quality evidence showing phenobarbital controlled seizures in 80% of neonates compared to only 28% with levetiracetam. 1
Important Exception - Suspected Channelopathy:
If there is a positive family history suggesting self-limited familial neonatal epilepsy (KCNQ2/KCNQ3 variants), use phenytoin or carbamazepine as first-line instead, as 91% of experts agreed sodium channel blockers are preferred in this scenario. 1
Second-Line Treatment (If Seizures Persist)
If seizures continue after first-line therapy, the approach depends on clinical context:
For most etiologies (HIE, stroke, hemorrhage):
- Phenytoin or levetiracetam are preferred second-line options 1
- Alternative options include midazolam or lidocaine
For suspected channelopathy (based on clinical or EEG features):
- Use a sodium channel blocker (phenytoin or carbamazepine) if not already given 1
For neonates with cardiac disorders:
- Levetiracetam is preferred as second-line to avoid cardiac effects of other agents 1
Concurrent Diagnostic Workup
While initiating treatment, simultaneously investigate etiology:
- Assess for HIE - Most common cause of neonatal seizures; if present, initiate therapeutic hypothermia which reduces seizure burden 1
- Rule out metabolic causes: Check calcium, magnesium, sodium, and comprehensive metabolic panel
- Consider infection: Obtain blood culture, consider lumbar puncture if clinically stable
- Neuroimaging: MRI is preferred when feasible to identify structural causes
- Consider pyridoxine trial if seizures are refractory to second-line therapy without identified etiology - give pyridoxine as add-on therapy 1
Critical Pitfalls to Avoid
Do not delay treatment waiting for EEG confirmation - Clinical seizures warrant immediate pharmacotherapy, though EEG should be obtained as soon as possible for ongoing monitoring.
Do not use levetiracetam as first-line - Despite its favorable side effect profile, evidence shows significantly lower efficacy (28%) compared to phenobarbital (80%) for seizure cessation. 1 Respiratory depression is more common with phenobarbital (17%) than levetiracetam (5%), but efficacy takes priority for acute seizure control.
Do not continue antiseizure medications long-term for acute provoked seizures - Following cessation of acute provoked seizures without evidence of neonatal-onset epilepsy, medications should be discontinued before discharge home, regardless of MRI or EEG background abnormalities. 1 This approach optimizes neurodevelopmental outcomes.
Treatment Algorithm Summary
- Stabilize (ABC, glucose correction, IV access)
- First-line: Phenobarbital 20 mg/kg IV (or sodium channel blocker if family history of channelopathy)
- If seizures persist: Additional 20 mg/kg phenobarbital OR switch to second-line (phenytoin/levetiracetam based on etiology)
- If still refractory: Consider pyridoxine trial, especially if no etiology identified 1
- Discontinue medications before discharge if acute provoked seizures have resolved 1
Treatment of electrographic seizures is associated with better neurodevelopmental outcomes and reduced likelihood of later epilepsy, making aggressive seizure control a priority. 1